

**ATTACHMENT B**  
**DDP Program Year 3 Orders and Liabilities**

<b>Pharmaceutical Company</b>	<b>Program Year 3 Liability</b>	<b>Order Period (OP) 1 Orders</b>	<b>DDP Liability Remaining Before OP2</b>	<b>OP2 Orders</b>	<b>DDP Liability Remaining</b>	<b>Total DDP Liability</b>	<b>% Remaining of Total DDP Liability</b>
AHP/American Cyanamid (Wyeth)	\$ 9,533,195	\$ 2,217,099	\$ 7,316,096	\$ 2,077,700	\$ 5,238,396	\$ 16,053,300	32.63%
SmithKline Beecham (Glaxo-Smithkline)	\$ 4,901,361	\$ 920,624	\$ 3,980,737	\$ 1,252,669	\$ 2,817,690	\$ 11,209,969	25.14%
Novartis	\$ 4,770,099	\$ 1,244,074	\$ 3,526,025	\$ 1,127,353	\$ 2,398,672	\$ 7,431,000	32.28%
Upjohn (Pharmacia)*	\$ 4,947,556	\$ 1,266,973	\$ 3,680,583	\$ 1,319,170	\$ 2,361,413	\$ 9,999,136	23.62%
Searle (Pharmacia)*	\$ 1,909,111	\$ 473,761	\$ 1,435,350	\$ 237,897	\$ 1,197,453	\$ 2,441,000	49.06%
Abbott	\$ 1,958,239	\$ 421,117	\$ 1,537,122	\$ 583,024	\$ 954,098	\$ 5,155,804	18.51%
Merck*	\$ 8,787,586	\$ 7,349,319	\$ 1,438,267	\$ 769,242	\$ 629,998	\$ 19,568,621	3.22%
Glaxo-Wellcome (Glaxo-SmithKline)	\$ 6,723,313	\$ 5,501,373	\$ 1,221,940	\$ 853,095	\$ 432,315	\$ 19,392,855	2.23%
Boehringer-Ingelheim*	\$ 934,567	\$ 259,668	\$ 674,899	\$ 257,916	\$ 416,983	\$ 2,519,314	16.55%
Rhone-Poulenc Rorer (Aventis)	\$ 1,539,350	\$ 534,682	\$ 1,004,668	\$ 677,180	\$ 327,488	\$ 2,968,493	11.03%
Zeneca*	\$ 2,281,131	\$ 2,042,556	\$ 238,575	\$ 189,854	\$ 132,019	\$ 5,819,809	2.27%
Knoll (Abbott)*	\$ 455,702	\$ 124,757	\$ 330,945	\$ 264,511	\$ 66,433	\$ 1,367,069	4.86%
Carter Wallace (Church & Dwight)	\$ 238,121	\$ 155,480	\$ 82,641	\$ 82,472	\$ 169	\$ 705,675	0.02%
Schering-Plough Schering*	\$ 2,788,012	\$ 1,957,052	\$ 830,960	\$ 830,825	\$ 135	\$ 8,339,123	0.00%
Pfizer*	\$ 3,994,365	\$ 3,944,689	\$ 49,676	\$ 49,609	\$ 67	\$ 11,795,856	0.00%
Roche	\$ 102,368	\$ 102,316	\$ 233,679	\$ 233,620	\$ 59	\$ 1,962,500	0.00%
Warner Lambert (Pfizer)	\$ 1,916,903	\$ 1,916,890	\$ 13	\$ -	\$ 13	\$ 5,702,632	0.00%
Dupont (Bristol Myers Squibb)	\$ 1,657,973	\$ 1,152,133	\$ 505,840	\$ 505,827	\$ 13	\$ 2,773,198	0.00%
Hoechst-Marion Roussel (Aventis)	\$ 4,364,290	\$ 1,225,364	\$ 3,138,926	\$ 3,138,920	\$ 6	\$ 6,366,500	0.00%
Bristol-Myers Squibb	\$ 5,312,485	\$ 5,312,479	\$ 6	\$ -	\$ 6	\$ 12,811,393	0.00%
Eli Lilly & Co.*	\$ 4,052,451	\$ 3,894,302	\$ 158,149	\$ 158,148	\$ 1	\$ 11,913,033	0.00%
Janssen (Johnson & Johnson)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 1,858,000	0.00%
Ortho-McNeil (Johnson & Johnson)	\$ 249,993	\$ 249,993	\$ -	\$ -	\$ -	\$ 2,998,500	0.00%
	\$ 73,418,169	\$ 42,266,701		\$ 14,609,032	\$ 16,973,427	\$ 171,152,780	

\*Has confirmed its agreement with Medpin figures for remaining DDP liability.

Note that companies NOT designated by an \* have not yet responded to Medpin's request for their confirmation of figures, or are currently researching the reason for any discrepancies between Medpin and company figures.